NextCure (NXTC) Accounts Payables (2018 - 2026)
NextCure (NXTC) posted quarterly Accounts Payables of $3.1 million for Q1 2026, up 12.21% year-over-year from $2.7 million in Q1 2025, and up 52.66% quarter-over-quarter from $2.0 million in Q4 2025.
NextCure (NXTC) Accounts Payables (2018 - 2026) Analysis & Trends
NextCure's Accounts Payables history runs 9 years deep, the most recent figure standing at $3.1 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 12.21% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (up 12.21% YoY), while the FY2025 annual figure was $2.0 million, down 62.43% from the prior year.
- Accounts Payables for Q1 2026 stood at $3.1 million, up from $2.0 million in the prior quarter.
- The five-year high for Accounts Payables was $5.4 million in Q4 2024, with the low at $1.8 million in Q3 2022.
- The 5-year median for Accounts Payables is $2.7 million (2025), against an average of $3.1 million.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables soared 134.03% in 2024, then sank 62.43% in 2025.
- NextCure's Accounts Payables stood at $4.3 million in 2022, then slumped by 45.43% to $2.3 million in 2023, then jumped by 129.74% to $5.4 million in 2024, then tumbled by 62.43% to $2.0 million in 2025, then jumped by 52.66% to $3.1 million in 2026.
- Business Quant data shows NXTC's Accounts Payables at $3.1 million in Q1 2026, $2.0 million in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.58 Mn |
| Mar 31, 2026 | 3.07 Mn |
| Dec 31, 2025 | 2.01 Mn |
| Sep 30, 2025 | 2.39 Mn |
| Jun 30, 2025 | 2.54 Mn |
| Mar 31, 2025 | 2.74 Mn |
| Dec 31, 2024 | 5.35 Mn |
| Sep 30, 2024 | 3.61 Mn |
| Jun 30, 2024 | 5.08 Mn |
| Mar 31, 2024 | 4.49 Mn |
| Dec 31, 2023 | 2.33 Mn |
| Sep 30, 2023 | 2.60 Mn |
| Jun 30, 2023 | 2.81 Mn |
| Mar 31, 2023 | 1.92 Mn |
| Dec 31, 2022 | 4.27 Mn |
| Sep 30, 2022 | 1.85 Mn |
| Jun 30, 2022 | 2.27 Mn |
| Mar 31, 2022 | 2.80 Mn |
| Dec 31, 2021 | 1.94 Mn |
| Sep 30, 2021 | 2.95 Mn |